The head of the U.N. AIDS agency says the sudden loss of American money has been “devastating” for efforts to stop HIV and ...

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.

Amid continuing uncertainty about the impact of deep US funding cuts to humanitarian work worldwide, the head of the UN ...

GENEVA: The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid ...

The UNAIDS director also warned that US funding cuts could be dire for global efforts to curb HIV. View on euronews ...

Lenacapavir' was developed by Gilead Sciences, a research-based biopharmaceutical company in the United States, as a pre-exposure prophylaxis (PrEP) medication to prevent infection in people at ...

The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...

By Gift BritonThe once-a-year injectable pre-exposure prophylaxis (PrEP), Lenacapavir, has shown promising results in a recent Phase 1 clinical trial.The trial involved 40 healthy adults aged between ...

It is the first time that a PrEP trial has been shown to prevent any HIV infections from slipping through the net, according to Gilead, and showed a subcutaneous injection with lenacapavir every ...

Data from both studies showcased the superiority of twice-yearly injectable, lenacapavir, compared to once-daily oral Truvada and background HIV incidence rates, prompting Gilead to unblind the ...